secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-02-07T23:59:59+00:00
Accession:  0001193125-22-029142
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX promotes Amy Peterson to President and COO; salary, equity grants disclosed
--------------------------------------------------------------------------------

- Dr. Peterson promoted to President and COO effective Feb 2, 2022; previously EVP & Chief Dev. Officer.
- Annual base salary increased to $550,000; discretionary annual bonus target set at 50% of salary.
- Received option for 200,000 shares at $4.13 strike price and 40,000 restricted stock units.
- Dr. Sean McCarthy continues as Chairman and CEO; Peterson assumes President role formerly held by McCarthy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/d198997d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-029142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer